Why Glaukos Corporation (GKOS) Stock Fell 6.3% on Oct 8, 2026
The clearest new catalyst: RevOpsis licensing deal announcement.
Why did GKOS stock fall?
Glaukos fell 6.3% on October 8, 2026, after announcing an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic for retinal diseases. The decline occurred despite concurrent positive clinical data, suggesting investor skepticism about deal economics, capital requirements, or near-term financial impact.
- RevOpsis licensing deal announcement: Glaukos announced an exclusive license agreement with RevOpsis Therapeutics for RO-104, a first-in-class tri-specific biologic targeting retinal diseases, expanding the company's pipeline but raising investor concerns about deal terms and capital deployment.
- Positive Epioxa three-year trial results: The company released three-year data for Epioxa demonstrating durable clinical outcomes in keratoconus treatment, showing patients maintained vision and corneal shape improvements three years after a single treatment—a positive clinical milestone that did not offset deal-related concerns.
Initial detection
BestStocks first flagged GKOS intraday on Oct 8, 2026; this analysis was finalized after the close using the confirmed −6.3% session move and additional catalyst research.
Show the initial intraday note
Glaukos announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic for retinal diseases (Business Wire). Despite the pipeline expansion, GKOS fell 12.63% to $150.43 from $172.18, on elevated volume of 850,206 shares (4.10x expected for 90 minutes into the session), suggesting investor concern about deal terms, capital requirements, or near-term financial impact.
What to watch next: Glaukos earnings on November 4, 2026 (date not yet confirmed); watch for management guidance on RO-104 development timeline, milestone payments, and impact on cash runway.
Other developments that session
Glaukos licensed exclusive rights to develop and commercialize RO-104, a first-in-class tri-specific biologic for retinal diseases.
Frequently asked questions
Why did Glaukos Corporation (GKOS) stock fall on Oct 8, 2026?
Glaukos fell 6.3% on October 8, 2026, after announcing an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic for retinal diseases. The decline occurred despite concurrent positive clinical data, suggesting investor skepticism about deal economics, capital requirements, or near-term financial impact.
How much did GKOS stock fall on Oct 8, 2026?
GKOS fell 6.3% during the Oct 8, 2026 trading session.
What were the main drivers behind GKOS's move?
RevOpsis licensing deal announcement; Positive Epioxa three-year trial results.